



FOR IMMEDIATE RELEASE

Contact: Holly P. Glass
holly.glass@semprusbio.com
703.754.2848

**SEMPRUS BIOSCIENCES APPOINTS
COLIN R. GARDNER, PH.D. & MICHAEL J. CIMA, PH.D.
TO SCIENTIFIC ADVISORY BOARD**

Cambridge, MA (March 29, 2010)—[Semprus BioSciences](#), Inc., today announced the appointment of Colin R. Gardner, Ph.D. and Michael J. Cima, Ph.D. as members of the company's [Scientific Advisory Board](#) (SAB). Both appointments are effective immediately.

Dr. Gardner is a widely recognized thought leader in the application of physical chemistry, chemical engineering and pharmaceutical sciences to the discovery and development of small molecule drugs and biologics. He serves a variety of clients as a private industry consultant. Previously, he held the position of Chief Scientific Officer at TransForm Pharmaceuticals, where he was responsible for building and applying the company's high throughput technical capabilities and developing contracts with other pharmaceutical companies. TransForm was acquired in 2005 by Johnson & Johnson, where Dr. Gardner assumed the role of Senior Vice President of Research and Site Leader for TransForm.

Prior to his tenure at TransForm/J&J, Dr. Gardner was Vice President of Pharmaceutical Research and Development at Merck & Co, where he was involved in the development of 16 new pharmaceutical products whose peak total annual sales exceeded \$20 billion, along with three vaccines.

Gardner holds a B.Sc. in Chemistry and Ph.D. in Physical Chemistry from the University of Glasgow, Scotland. After post-doctoral experience in Biophysics at Harvard University and Chemical Engineering at Massachusetts Institute of Technology, he was a SRC Fellow at the University of Aberdeen, Scotland. Dr. Gardner then joined the Merrell International Research Center in Strasbourg, France, where he was a Senior Scientist in Biochemistry and Pharmacology.

Professor Cima is the Sumitomo Electric Industries Professor in the Department of Materials Science and Engineering at Massachusetts Institute of Technology. He is also an Investigator at the Koch Institute for Integrative Cancer Research, and a Director at Convergence Products Research Laboratory. He holds numerous external appointments as both Co-Founder and Director of MicroChips, Inc., Taris Biomedical, Inc., Entra Pharmaceuticals, Inc., T2 Biosystems, Inc. and was a senior consultant at TransForm Pharmaceuticals, Inc. – where he served as a member of its management team.

Professor Cima earned a B.S. in Chemistry and a Ph.D. in Chemical Engineering from the University of California at Berkeley. He is author or co-author of more than two hundred peer reviewed scientific publications, 37 U.S. patents, and is a recognized expert in the field of materials processing. Professor Cima is actively involved in materials and engineered systems for improvement in human health – such as treatments for cancer, metabolic diseases, trauma and urological disorders. He is the recipient of many prominent awards and honors, including the Fulrath Award, International Award of Materials Engineering for Resources, Sumitomo Electric Industries Chair, Fellow of the American Ceramics Society R&D 100 Award for 3DP Applied to Metal Casting.

(more)

“We are delighted and honored to welcome Colin and Michael to our Scientific Advisory Board,” said Semprus BioSciences Chief Executive Officer, [David L. Lucchino](#). “Their extensive expertise in biochemistry and the life sciences is internationally recognized,” he said, “and is an invaluable resource for Semprus BioSciences.” As we deliver the first complication-free, anti-biofilm, anti-thrombogenic medical devices to the market, [Semprus BioSciences](#) is poised to establish a new standard-of-care with a diverse range of implantable medical devices, from hernia meshes and orthopedics to CRM devices.”

###

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed (5AM Venures and Pangaea Ventures) biomedical company that in 2007 spun out of the famed labs of MIT researcher Dr. Robert Langer. Semprus' next generation solution has a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to health care cost efficiencies. Our innovative, multi-faceted Semprus Surfaces™ signifies a breakthrough in medical device technology. Our current focus is to enable a foundation of an anti-colonization and anti-thrombogenic solution that can deliver the first permanently dual-functional vascular access catheter with a single surface modification. This multi-dimensional Semprus Surfaces™ technology can also provide a long lasting anti-biofilm surface, which is designed to deliver drugs and presents multiple co-immobilized agents off this surface to address a wide range on clinical problems. Visit www.semprusbio.com for additional information.